GRASP cystatin c in serum, early response to treatment in pediatric acute lymphoblastic leukemia treatment, end-of-induction minimal residual disease (pediatric acute lymphoblastic leukemia treatment), pulmonary arterial hypertension (pah), resistance to kuru in aged women despite likely exposure, stabilized warfarin dose